PD-1 and CD160 are overexpressed in persisting transgenic lymphocytes. (A) Percentages of PD-1 expression in infusion and postinfusion CD8 T cells. (B) Reduced IFNγ production in CD8 T cells cocultured in vitro with relevant targets engineered to expressed PD-L1. (C) LAG-3, 2B4, and CD160 exhaustion markers surface expression in CD3⁺CD8⁺mTCRb⁺ infusion and postinfusion lymphocytes. Cells wre gated on lymphoid, PI⁻, CD3⁺, CD8⁺, mTCRb⁺ cells. (D) HVEM surface expression in melanoma tumor cells present in tumor digests of 4 melanoma patients. (E) Histograms showing surface staining of CD160 and costimulatory receptor LIGHT in persisting engineered lymphocytes of 5 patients. In all samples analyzed, LIGHT expression was lower than that of CD160.